- Details
- Yair Lotan discusses the advancements in the ability to detect bladder cancer and bladder cancer recurrence in the clinic with blue light cystoscopy. Until recently, the technology was only available in the OR but now, with the approval of blue light flexible cystoscopy bladder cancer surveillance can now be done in the clinic. The blue light cystoscopy with CYSVIEW is performed in the clinic to d...
|
- Details
- Yair Lotan discusses the recently published consensus statement on flexible blue light cystoscopy (BLC™) with Cysview ® . His presentation is centered around the published consensus in Nature Reviews developed by multiple experts (authors) in bladder cancer. Yair discusses the role of blue light flexible cystoscopy with CYSVIEW in non-muscle invasive bladder cancer. The expert consensus group met...
|
- Details
- Rebecca Roe speaks to an interdisciplinary approach to implementation of Blue Light Cystoscopy (BLC™) in her community hospital center, giving a Clinical Education Program Coordinator's perspective. Her team engaged in the five management practices looking at ongoing communication and clinical training and measured things along the way, seeking feedback from every discipline that was utilized, whe...
|
- Details
- Joshua Meeks joins Alicia Morgans to review his approach to cystoscopy using blue light and Cysview®, and how to best choose patients that will maximally benefit from that kind of technology. Dr. Meeks and Dr. Morgans also review the new approval of pembrolizumab in the BCG unresponsive high-risk non-muscle invasive bladder cancer (NMIBC). Biographies: Josh J. Meeks, MD, Ph.D., Assistant Professor...
|
- Details
- Stephen Williams discusses the macro and microeconomics of using blue light cystoscopy with CYSVIEW ® in nonmuscle invasive bladder cancer compared to white light cystoscopy alone. Dr. Williams notes that cancer care is expected to increase from $158 to $174 billion dollars between 2010 and 2020 due to increasing cancer incidence, improved survival outcomes, and an expanding healthcare market. Cos...
|
- Details
- Trinity Bivalacqua joins Ashish Kamat to discuss the role of blue light cystoscopy in bladder cancer treatment, specifically regarding non-muscle invasive disease. Dr. Bivalacqua emphasizes how risk stratification allows for personalization of care and highlights a case study of a patient with high-risk non-muscle invasive bladder cancer. Dr. Bivalacqua also explains how blue light cystoscopy can...
|
- Details
- Anne Schuckman, MD, MBBS, presents a summary of her plenary session presentation from the AUA 2020 live virtual conference on benefits of Blue Light Cystoscopy (BLC ® ) with Cysview ® , in a conversation with Ashish Kamat, MD. Dr. Schuckman details how Cysview can be used to visualize bladder tumors and highlights benefits arising from this technique including an increased ability to resect the tu...
|
- Details
- Yair Lotan, MD, and Daniel Parker, MD join Ashish Kamat, MD, MBBS in a discussion on the efficacy and utilization of Blue Light Cystoscopy (BLC) Cysview® (hexaminolevulinate HCl). Dr. Lotanoffers his perspective on the use of blue light cystoscopy in bladder cancer detection in the hospital and Dr. Parker offers his perspective on the use in the office. Studies have shown that BLC improves the det...
|
- Details
- Badrinath Konety presents Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry. Blue light cystoscopy (BLC) using hexaminolevulinate HCL (Cysview®) has been previously shown to improve the detection of non-muscle-invasive bladder cancer (NMIBC). The objective of this study was to evaluate the detection of malignant lesions in a heterogenou...
|
- Details
- Sia Daneshmand joins Ashish Kamat in a conversation on the phase III trial comparing blue light flexible cystoscopy with white light flexible cystoscopy for the detection of bladder cancer during surveillance. This study shows significant improvement of the detection of patients with recurrent bladder cancer and for the detection of carcinoma in situ, detecting lesions that are missed with white l...
|
